Monday, April 25, 2011

Summer Workshops in Biopharmaceutical Production

Mtech Summer Workshops in Biopharmaceutical Production

Are you interested in advancing your career in biopharmaceutical processing? Learn how to produce and purify biopharmaceutical products at the University of Maryland from June 6-10, 2011.

Offered through the university's Maryland Technology Enterprise Institute (Mtech) Biotechnology Research and Education Program, this hands-on, one-week training features two distinct sessions, a Fermentation and Microbiology Workshop from June 6-7, and a Downstream Processing & Protein Purification Workshop from June 8-10.

The two Biopharmaceutical Production training sessions:
June 6-7, 2011: Fermentation Microbiology Workshop
This session features hands-on instruction with various fermentation systems and acquaints attendees with the techniques, methodologies, principles and applications of aerobic bacterial and fungal fermentation. The workshop provides an opportunity for participants not only to learn the principles of bacterial and fungal fermentation scale-up at the bench, but also covers recent advances and up-to-date applications of this methodology.

June 8-10, 2011: Downstream Processing & Protein Purification Workshop
This workshop features hands-on laboratory exercises and classroom instruction on recovery and purification strategies for biotechnology products, especially proteins. Participants will integrate theory with practice in areas such as cell separation, cell disruption, chromatography theory and systems, sample preparation, columns and packing, adsorptive chromatography, and elution optimization.
More information about these workshops can be found here.


  1. This is so interesting and informative post this good news. Because large majority of biopharmaceutical products are pharmaceuticals that are derived from life forms. Small molecule drugs are not typically regarded as biopharmaceutical in nature by the industry.
    When a biopharmaceutical is developed, the company will typically apply for a patent, which is a grant for exclusive manufacturing rights. This is the primary means by which the developer of the drug can recover the investment cost for development of the biopharmaceutical. So I think this is so big news at this time.